News, Events and Updates

February 7, 2018


Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results

October 12, 2017


Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET

March 13, 2017


Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference

November 8, 2017


Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC

April 3, 2017


Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor

May 9, 2018


Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018

March 15, 2017


Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference

May 17, 2017


Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.

November 21, 2017


Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor

April 17, 2018


Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome

March 9, 2018


Anavex Life Sciences to Present at the 30th Annual ROTH Conference

June 5, 2018


Anavex participates on Brain Health panel at Bio International Conference in Boston